secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000875320-23-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B
-----------------------------------------------------------------------------

- Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).
- FY2023 product revenue guidance raised to ~$9.85B (from $9.7-9.8B); opex guidance unchanged.
- Exa-cel PDUFA for SCD Dec 8, 2023; BLA Priority Review; EU/UK reviews ongoing.
- Phase 3 data for vanzacaftor triple and VX-548 acute pain expected early 2024; Phase 2 neuropathic pain data late 2023.
- Cash and marketable securities $13.6B at Sep 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/vrtx-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000875320-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer